Theravance Biopharma TBPH Increase Decrease In Receivables From Collaboration Partners
Increase Decrease In Receivables From Collaboration Partners at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept tbph:IncreaseDecreaseInReceivablesFromCollaborationPartners.
The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Theravance Biopharma's increase decrease in receivables from collaboration partners.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Theravance Biopharma's increase decrease in receivables from collaboration partners?
- Theravance Biopharma (TBPH) reported increase decrease in receivables from collaboration partners of -$29.95M in Q1 2026.
- How has Theravance Biopharma's increase decrease in receivables from collaboration partners changed year-over-year?
- Theravance Biopharma's increase decrease in receivables from collaboration partners decreased by 870.3% year-over-year, from -$3.09M to -$29.95M.
- What is the long-term trend for Theravance Biopharma's increase decrease in receivables from collaboration partners?
- Over 3 years (2022 to 2025), Theravance Biopharma's increase decrease in receivables from collaboration partners has grown at a 115.2% compound annual growth rate (CAGR), from $2.72M to $27.1M.
- What does increase decrease in receivables from collaboration partners mean?
- This measures the change in outstanding balances owed by collaboration partners for services rendered or milestones achieved. A decrease indicates effective cash collection from partners, while an increase suggests a buildup of uncollected revenue. It is a key indicator of working capital efficiency and the timing of cash inflows from strategic partnerships.